• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Humana Inc. to Release Third Quarter 2024 Results on October 30, 2024

    9/30/24 4:30:00 PM ET
    $HUM
    Medical Specialities
    Health Care
    Get the next $HUM alert in real time by email

    Humana Inc. (NYSE:HUM) will release its financial results for the third quarter 2024 (3Q24), as well as prepared management remarks (in PDF format), on Wednesday, October 30, 2024, at 6:30 a.m. Eastern time. The company will host a live question and answer session at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2024.

    To participate via telephone, please register in advance using this link, https://register.vevent.com/register/BI66effa11b1e4494d907df29b87d7d237.

    Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique registrant ID.

    A webcast of the 3Q24 earnings call may also be accessed via Humana's Investor Relations page at https://humana.gcs-web.com/.

    The company suggests participants for both the conference call and those listening via the web dial in or sign on at least 15 minutes in advance of the call. For those unable to participate in the live event, the virtual presentation archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page at https://humana.gcs-web.com/, approximately two hours following the live webcast.

    The company's 3Q24 earnings news release is expected to include financial measures that are not in accordance with Generally Accepted Accounting Principles (GAAP). A reconciliation of non-GAAP financial measures to financial results under GAAP, as well as management's reasons for including non-GAAP financial measures, will be included in the company's 3Q24 earnings news release, a copy of which will be available on the Investor Relations page of www.humana.com on October 30, 2024.

    About Humana

    Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240930201812/en/

    Get the next $HUM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HUM

    DatePrice TargetRatingAnalyst
    5/1/2025$315.00Mkt Perform → Outperform
    Raymond James
    11/6/2024$247.00 → $308.00Underperform → Neutral
    BofA Securities
    10/11/2024Sector Weight
    KeyBanc Capital Markets
    10/8/2024$308.00Mkt Perform → Outperform
    Bernstein
    10/7/2024$402.00 → $261.00Buy → Hold
    TD Cowen
    10/7/2024$519.00 → $253.00Buy → Hold
    Jefferies
    10/3/2024$392.00 → $274.00Overweight → Neutral
    Piper Sandler
    10/2/2024$376.00 → $247.00Neutral → Underperform
    BofA Securities
    More analyst ratings